JP2001503028A - 内皮損傷の治療方法 - Google Patents

内皮損傷の治療方法

Info

Publication number
JP2001503028A
JP2001503028A JP10513794A JP51379498A JP2001503028A JP 2001503028 A JP2001503028 A JP 2001503028A JP 10513794 A JP10513794 A JP 10513794A JP 51379498 A JP51379498 A JP 51379498A JP 2001503028 A JP2001503028 A JP 2001503028A
Authority
JP
Japan
Prior art keywords
endothelial
chemotherapeutic agent
erythropoietin
epo
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP10513794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503028A5 (enExample
Inventor
アナグノストウ，アサナシウス・エイ
シゴウナス，ジョージ
Original Assignee
イースト・キャロライナ・ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24861777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2001503028(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イースト・キャロライナ・ユニヴァーシティ filed Critical イースト・キャロライナ・ユニヴァーシティ
Publication of JP2001503028A publication Critical patent/JP2001503028A/ja
Publication of JP2001503028A5 publication Critical patent/JP2001503028A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP10513794A 1996-09-11 1997-09-10 内皮損傷の治療方法 Withdrawn JP2001503028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
US08/712,358 1996-09-11
PCT/US1997/015966 WO1998010650A1 (en) 1996-09-11 1997-09-10 Method of treating endothelial injury

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008048009A Division JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A Division JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤

Publications (2)

Publication Number Publication Date
JP2001503028A true JP2001503028A (ja) 2001-03-06
JP2001503028A5 JP2001503028A5 (enExample) 2005-04-07

Family

ID=24861777

Family Applications (3)

Application Number Title Priority Date Filing Date
JP10513794A Withdrawn JP2001503028A (ja) 1996-09-11 1997-09-10 内皮損傷の治療方法
JP2008048009A Pending JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A Pending JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2008048009A Pending JP2008133305A (ja) 1996-09-11 2008-02-28 内皮細胞の阻止作用を強化する薬剤
JP2009086240A Pending JP2009196999A (ja) 1996-09-11 2009-03-31 内皮細胞の損傷を減らす薬剤

Country Status (11)

Country Link
US (5) US20020052309A1 (enExample)
EP (1) EP0933995B8 (enExample)
JP (3) JP2001503028A (enExample)
CN (2) CN1113669C (enExample)
AT (1) ATE282425T1 (enExample)
CA (1) CA2265547C (enExample)
DE (1) DE69731652T2 (enExample)
DK (1) DK0933995T3 (enExample)
ES (1) ES2231889T3 (enExample)
PT (1) PT933995E (enExample)
WO (1) WO1998010650A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
TR200103785T2 (tr) * 1999-04-13 2002-06-21 The Kenneth S. Warren Institute, Inc. Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
WO2000067776A1 (en) * 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
DE60131393D1 (de) * 2000-05-02 2007-12-27 Action Pharma As Verfahren zur behandlung von erkrankungen assoziiert mit akuten entzündung unter nichtischämischen zustände
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
DK1459762T3 (da) * 2001-11-02 2008-10-06 Yoshiko Yasuda Anvendelse af EMP9 til forebyggelse af proliferative organsygdomme
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CN1897959A (zh) * 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
WO2005099773A1 (en) * 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP4340865A4 (en) * 2021-05-18 2025-04-02 Attias, Eyal USE OF ERYTHROPOIETIN (EPO) OR ERYTHROPOIESIS STIMULATING AGENT (ESA) FOR THE TREATMENT OF OSTEOMYELITIS, BONE INFECTION AND BONE INFLAMMATION

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
JP2001520503A (ja) * 1994-12-30 2001-10-30 カイロン コーポレイション インビボにおける固形腫瘍の処置のための方法および組成物
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN4007020778, 漆崎一朗, "特集 サイトカインと癌化学療法 サイトカインと抗癌剤の併用理論と実際", 化学療法の領域, 199406, Ｖｏｌ．１０， Ｎｏ．６, ｐ．１０３１−１０３７, JP, 株式会社 医薬ジャーナル社 *
JPN4007020779, ＡＮＡＧＮＯＳＴＯＵ， Ａ．， ｅｔ ａｌ．, "Ｅｒｙｔｈｒｏｐｏｉｅｔｉｎ ｈａｓ ａ ｍｉｔｏｇｅｎｉｃ ａｎｄ ｐｏｓｉｔｉｖｅ ｃｈｅｍｏｔａｃｔｉｃ ｅｆｆｅｃｔ ｏｎ ｅｎｄｏｔｈｅｌｉａｌ ｃｅｌｌｓ", Ｐｒｏｃｅｅｄｉｎｇｓ ｏｆ ｔｈｅ Ｎａｔｉｏｎａｌ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ ｏｆ ｔｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ, 199008, Ｖｏｌ．８７， Ｎｏ．１５, ｐ．５９７８−５９８２, US *
JPN4007020780, 藤岡知昭， 他．, "遺伝子組み換えエリスロポエチンの腎癌細胞の増殖および腫よう血管新生に与える影響", 自己血輸血, 199508, Ｖｏｌ．８， Ｎｏ．１, ｐ．４６−５０, JP *
JPN4007020781, 永井哲士, "ｒＨｕＥＰＯがヒト血管内皮細胞の増殖とＥｎｄｏｔｈｅｌｉｎ−１産生に及ぼす影響", 日本腎臓学会誌, 199403, Ｖｏｌ．３６， Ｎｏ．３, ｐ．１９４−２００, JP *
JPN6010013846, 大東弘明， 他．, "抗癌剤による血管内皮障害と血行性転移", 癌と化学療法, 19940930, Ｖｏｌ．２１， Ｎｏ．１３, ｐ．２１７２−２１７５, JP, 出版法人 癌と化学療法社 *
JPN6010013849, ＩＴＯ， Ｈ．， ｅｔ ａｌ．, "Ｖｉｔａｍｉｎ Ｅ ｐｒｅｖｅｎｔｓ ｅｎｄｏｔｈｅｌｉａｌ ｉｎｊｕｒｙ ａｓｓｏｃｉａｔｅｄ ｗｉｔｈ ｃｉｓｐｌａｔｉｎ ｉｎｊｅｃｔｉｏｎ ｉｎｔｏ ｔｈｅ ｓｕｐｅｒｉｏｒ ｍｅｓｅｎｔｅｒ", Ｈｅａｒｔ Ｖｅｓｓｅｌｓ, 1995, Ｖｏｌ．１０， Ｎｏ．４, ｐ．１７８−１８４ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510734A (ja) * 2003-11-07 2007-04-26 ザ ヘンリー エム． ジャクソン ファウンデイション 低酸素誘導性遺伝子発現の活性化
WO2008050836A1 (en) * 2006-10-25 2008-05-02 Ajinomoto Co., Inc. Agent for ameliorating adverse side-effect of chemotherapeutic agent

Also Published As

Publication number Publication date
CN1250281C (zh) 2006-04-12
DE69731652D1 (de) 2004-12-23
EP0933995A1 (en) 1999-08-11
EP0933995B1 (en) 2004-11-17
CN1235512A (zh) 1999-11-17
CN1429623A (zh) 2003-07-16
DK0933995T3 (da) 2005-02-14
HK1022810A1 (en) 2000-08-25
US7531501B1 (en) 2009-05-12
ATE282425T1 (de) 2004-12-15
CN1113669C (zh) 2003-07-09
CA2265547C (en) 2009-12-01
US7803408B2 (en) 2010-09-28
JP2008133305A (ja) 2008-06-12
JP2009196999A (ja) 2009-09-03
EP0933995A4 (en) 2002-08-28
US20090285908A1 (en) 2009-11-19
WO1998010650A1 (en) 1998-03-19
CA2265547A1 (en) 1998-03-19
DE69731652T2 (de) 2005-12-15
US20020052309A1 (en) 2002-05-02
ES2231889T3 (es) 2005-05-16
US5922674A (en) 1999-07-13
US20080124401A1 (en) 2008-05-29
PT933995E (pt) 2005-02-28
EP0933995B8 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
JP2009196999A (ja) 内皮細胞の損傷を減らす薬剤
US6610699B2 (en) Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US8703709B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
EA009939B1 (ru) Жирные кислоты со средней длиной цепи, глицериды и аналоги в качестве стимуляторов эритропоэза
RU2296563C2 (ru) Эритропоэтин облегчает in vivo токсичность, индуцированную химиотерапией
EP0774255B1 (en) Use of ursolic acid for the manufacture of a medicament for suppressing metastasis
US8729023B2 (en) Methods, compositions and articles of manufacture for contributing to the treatment of cancers
KR102527457B1 (ko) 혈구 감소증의 치료 또는 지속 기간 감소를 위한 포르볼 에스테르 조성물 및 그 사용 방법
PT99265B (pt) Processo para a preparacao de composicoes farmaceuticas contendo interferon humano e metodo de tratamento de doencas proliferativas celulares
US8349802B2 (en) Methods and compositions for contributing to the treatment of cancers
Cooper et al. Interferons in the treatment of multiple myeloma
CA2304956C (en) Pharmaceutical composition for preventing or treating ischemic diseases
EP0588477A2 (en) Medicinal composition comprising TCF-II
DE69028020T2 (de) Antitumorzusammensetzung die polypeptide mit der aktivität des humanen interleukin-2 enthält
CA2598439A1 (en) Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
EP3570849B1 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
HK1022810B (en) Method of treating endothelial injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100716

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100916

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110606

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110614

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110803